Print
Email
Print Edition Stories
MHT's Jackie Noblett: VC funds run short in 2009
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
MHT's Julie Donnelly: Life science startups finding investments
A new fund for Boston life sciences venture capital firm MPM BioVentures appears to be growing fast. Hours after Mass High Tech first reported a $69.1 million first close on MPM BioVentures V, the firm filed an amended disclosure, reporting the fund has now reached $140 million.
The amended filing still reports the firm’s fundraising target is “indefinite.” MPM’s last fund, MPM BioVentures IV, closed in March 2007 at $550 million.
MPM founder Ansbert Gadicke could not immediately be reached. An assistant to Gadicke said the firm has a policy of not speaking to members of the media.
According to MPM’s website, the firm invests in biotech, specialty pharma, medical technology and related areas providing medical products and services to the health-care industry. The firm does not have a geographic or stage focus. Its recent investments include Waltham-based Proteon Therapeutics Inc., Taiwanese TaiGen Biotechnology Co. Ltd., and Fremont, Calif.-based ARYx Therapeutics Inc. The firm is part of MPM Capital, which has more than $2.5 billion in managed capital between its MPM BioVentures and MPM BioEquities funds.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
